Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in Moderate-to-Severe Thyroid Eye Disease
NCT05987423Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of satralizumab in thyroid eye disease (TED), sponsored by Roche. Started Oct 2023; status: completed.
02
Drugs
satralizumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05987423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987423.